Other languages Hubei Biocause Pharmaceutical Co., Ltd.

Equities

000627

CNE000000F48

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
2.31 ^CNY	0.00%		-2.94%	-18.66%

04-29	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-15	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023	01-15
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period	14/08/23
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period	12/06/23
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023	22/05/23
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income	16/05/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022	24/04/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022	24/05/22
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	05/05/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/10/21
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	30/08/21
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020, Payable 04 June 2021	28/05/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hubei Biocause Pharmaceutical Co., Ltd.

Equities

000627

CNE000000F48

Other languages

Filters